Drug
Cd38 Sada 177lu Dota Complex
Cd38 Sada 177lu Dota Complex: highest development phase Phase 1, developed by Y-mAbs Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Y-mAbs Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| CD38-SADA:177Lu-DOTA Complex NCT05994157 | Phase 1 | Non-hodgkin Lymphoma |
Latest
No recent events.
Follow Cd38 Sada 177lu Dota Complex on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.